News

Filter

1 to 9 of 16 results

Teva gets positive UK judgment in case against AstraZeneca

Teva gets positive UK judgment in case against AstraZeneca

03-09-2014

A positive judgment has been given by the UK High Court in support of Israeli generic drug giant Teva…

AstraZenecaDuoResp SpiromaxGenericsLegalPatentsRespiratory and PulmonarySymbicortTeva Pharmaceutical IndustriesUK

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics

14-08-2014

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

Generic pains for AstraZeneca exacerbated by Indian drugmakers

Generic pains for AstraZeneca exacerbated by Indian drugmakers

06-04-2014

Indian generic companies are taking aim at mega blockbusters, and AstraZeneca, the $25.7 billion pharmaceutical…

Asia-PacificAstraZenecaDr Reddy's LaboratoriesFinancialGastro-intestinalsGenericsIndiaMarkets & MarketingNexiumPharmaceuticalPulmicortRanbaxy LaboratoriesRespiratory and PulmonarySymbicortUSAVimovo

Positive CHMP opinion for Teva’s DuoResp Spiromax for asthma and COPD

22-02-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive…

AstraZenecaDuoResp SpiromaxPharmaceuticalRegulationRespiratory and PulmonarySymbicortTeva Pharmaceutical Industries

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

06-02-2014

‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal…

AstraZenecaBrilintaCardio-vascularCrestorDiabetesExenatide InjectionFinancialInterviewsNexiumOncologyPharmaceuticalRespiratory and PulmonarySymbicortUK

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort

30-05-2013

US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

Asthma preventive drugs market led by GlaxoSmithKline's Advair

26-11-2012

The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

AdvairAstraZenecaGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicort

1 to 9 of 16 results

Back to top